Literature DB >> 21525722

Expression of ERβ and its co-regulators p300 and NCoR in human transitional cell bladder cancer.

Stylianos Kontos1, Athanasios Papatsoris, Athina Kominea, Maria Melachrinou, Anna Tanoglidi, Stefanos Kachrilas, Markos Karavitakis, Eleni Balampani, Georgia Sotiropoulou-Bonikou.   

Abstract

OBJECTIVE: Several data support a possible role of estrogens in bladder carcinogenesis, mediated mainly through estrogen receptor-β (ERβ). We study the expression of ERβ and its co-regulators p300 and nuclear co-repressor (NCoR) in patients with bladder cancer. PATIENTS AND METHODS: One hundred and eleven consecutive patients (74 males and 37 females), aged 23-90 years (mean 70 ± 10) diagnosed with transitional cell bladder cancer were included in this study. The control group consisted of 29 patients that underwent transurethral prostatectomy and consented to simultaneous bladder biopsies. Immunohistochemical studies took place on formalin-fixed, paraffin-embedded sections from the TUR (transurethral resection) specimens. We studied the expression of ERβ, p300 and NCoR.χ(2) test was used to evaluate the relationship between the histological grade and ERβ expression, grade and co-regulators expression and grade and gender. Spearman rank correlation coefficient (r) was used in order to estimate the direction and strength of correlations between histological grade and ERβ-p300-NCoR expressions. The Cochran-Armitage test for trend was applied in order to examine possible trends across the ordered levels of histological grade.
RESULTS: ERβ was more frequently expressed in the nucleus of normal bladder epithelium compared to malignant bladder epithelium with statistical significant association (r = -0.25, p = 0.003). The p300 was expressed only in the nucleus of bladder cancer cells and a positive correlation between molecular expression and cancer progression was demonstrated (r = 0.55, p < 0.001). NCoR immunostaining was demonstrated in the nuclei of bladder cells. Nuclear staining was significantly higher in normal tissue than in cancer cells (r = -0.33, p < 0.001), with negative correlation. Furthermore, its expression in grade I tumors was significantly higher than in grade II (r = -0.46, p < 0.001) and grade III tumors (r = -0.51, p < 0.001). Thus, like ERβ, NCoR expression in bladder epithelium decreased during cancer progression and loss of cell differentiation. There was no correlation between the levels of expression of the three proteins in normal bladder epithelium, but there was an inverse correlation between the nuclear expression of ERβ and p300 in carcinomas (r = -3.88, p = 0.042). Statistical significant association was established when correlating ERβ expression with NCoR expression (r = 0.273, p = 0.005), while co-regulators' nuclear expression did not correlate with each other (p > 0.05).
CONCLUSIONS: In bladder carcinogenesis, we demonstrated inhibition in the expression of ERβ and its co-repressor NCoR as well as increased expression of the co-activator p300.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21525722     DOI: 10.1159/000324262

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  7 in total

1.  Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch.

Authors:  Bangmin Han; Di Cui; Yifeng Jing; Yan Hong; Shujie Xia
Journal:  World J Urol       Date:  2014-02       Impact factor: 4.226

2.  Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer.

Authors:  Patrick Vianna Garcia; Letícia Montanholi Apolinário; Petra Karla Böckelmann; Iseu da Silva Nunes; Nelson Duran; Wagner José Fávaro
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Chemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen.

Authors:  Suraj Konnath George; Veronica Tovar-Sepulveda; Steven S Shen; Weiguo Jian; Yiqun Zhang; Susan G Hilsenbeck; Seth P Lerner; Carolyn L Smith
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

4.  Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch.

Authors:  Bangmin Han; Di Cui; Yifeng Jing; Yan Hong; Shujie Xia
Journal:  World J Urol       Date:  2012-01-12       Impact factor: 4.226

5.  Genistein sensitizes bladder cancer cells to HCPT treatment in vitro and in vivo via ATM/NF-κB/IKK pathway-induced apoptosis.

Authors:  Yong Wang; He Wang; Wei Zhang; Chen Shao; Peng Xu; Chang Hong Shi; Jian Guo Shi; Yu Mei Li; Qiang Fu; Wei Xue; Yong Hua Lei; Jing Yu Gao; Juan Ying Wang; Xiao Ping Gao; Jin Qing Li; Jian Lin Yuan; Yun Tao Zhang
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

6.  Estrogen receptor-β expression and pharmacological targeting in bladder cancer.

Authors:  Eric C Kauffman; Brian D Robinson; Martin Downes; Katarzyna Marcinkiewicz; Srinivas Vourganti; Douglas S Scherr; Lorraine J Gudas; Nigel P Mongan
Journal:  Oncol Rep       Date:  2013-04-23       Impact factor: 3.906

7.  Association Between Estrogen Receptors and GATA3 in Bladder Cancer: A Systematic Review and Meta-Analysis of Their Clinicopathological Significance.

Authors:  Carina Bernardo; Fátima L Monteiro; Inês Direito; Francisco Amado; Vera Afreixo; Lúcio L Santos; Luisa A Helguero
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-08       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.